文献速递肝病

荟萃分析:白蛋白预防和治疗肝硬化患者并发症的疗效与安全性

Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-15

该系统评价纳入50项随机对照试验共5118例肝硬化患者,评估白蛋白对比其他治疗或无活性干预的疗效与安全性。白蛋白可降低自发性细菌性腹膜炎和肝性脑病患者的死亡率,长期给药可能降低肝硬化并发症风险及腹腔穿刺需求。

要点

  • 白蛋白降低自发性细菌性腹膜炎患者死亡率(RR 0.49,95%CI 0.32-0.75;低确定性)。
  • 白蛋白降低肝性脑病患者死亡率(RR 0.53,95%CI 0.34-0.83;低确定性)。
  • 长期(>3个月)白蛋白给药可能降低肝硬化并发症风险(RR 0.75,95%CI 0.57-0.97;低确定性)。

核心结论

  • 白蛋白可能降低自发性细菌性腹膜炎或肝性脑病肝硬化患者的死亡风险,未发现减少肝移植或严重不良事件的获益。
  • 长期给药可能与较低的肝硬化并发症风险和腹腔穿刺需求相关。

研究设计与样本

  • 系统评价与荟萃分析,纳入MEDLINE、EMBASE和CENTRAL中截至2022年5月发表的随机对照试验。
  • 共纳入50项研究,5118例参与者。
  • 采用Mantel-Haenszel法和随机效应模型进行荟萃分析。

主要发现

  • 与不给予白蛋白相比,白蛋白与自发性细菌性腹膜炎患者死亡率降低相关(RR 0.49,95%CI 0.32-0.75;低确定性)。
  • 与不给予白蛋白相比,白蛋白与肝性脑病患者死亡率降低相关(RR 0.53,95%CI 0.34-0.83;低确定性)。
  • 在其他场景中未发现白蛋白的额外获益。
  • 总体上,白蛋白在肝移植、严重不良事件或肝硬化并发症方面未显示额外获益(低/极低确定性)。
  • 长期(>3个月)给予白蛋白导致肝硬化并发症减少(RR 0.75,95%CI 0.57-0.97;低确定性),并减少再入院、住院时间、腹腔穿刺需求及改善生活质量。

关键数值与推荐

  • 自发性细菌性腹膜炎患者:白蛋白 vs 不给予白蛋白,死亡率 RR 0.49(95%CI 0.32-0.75;低确定性)。
  • 肝性脑病患者:白蛋白 vs 不给予白蛋白,死亡率 RR 0.53(95%CI 0.34-0.83;低确定性)。
  • 长期(>3个月)白蛋白给药:肝硬化并发症 RR 0.75(95%CI 0.57-0.97;低确定性)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Albumin is used in multiple situations in patients with cirrhosis, but the evidence of its benefit is not always clear. The aim was to synthesise the evidence on the efficacy and safety of albumin compared to other treatments or no active intervention in cirrhotic patients. MATERIALS AND METHODS: We conducted a systematic review including randomised controlled trials (RCTs) published in MEDLINE, EMBASE and CENTRAL up to May 2022. We assessed all-cause mortality, liver transplant, cirrhosis complications of any type and serious adverse events (SAEs). Second, AEs, hospital readmission, length of hospital stay, need for paracentesis and quality of life (QoL) were evaluated. Meta-analyses with Mantel-Haenszel method and random-effects model were performed. RESULTS: Fifty studies (5118 participants) were included. Albumin was associated with a reduction in mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP) (RR 0.49, 95% CI 0.32-0.75; low certainty) and hepatic encephalopathy (HE) (RR 0.53, 95% CI 0.34-0.83; low certainty) when compared to no administration of albumin, but not in other scenarios. In general, no additional benefit of albumin was found in liver transplants, SAEs or cirrhosis complications (low/very low certainty). Long-term administration (>3 months) of albumin led to a reduction in cirrhosis complications (RR 0.75, 95% CI 0.57-0.97; low certainty), hospital readmissions, length of hospital stay, need for paracentesis and improvement of QoL. CONCLUSION: Albumin may reduce mortality risk in cirrhotic patients with SBP or HE. No benefit was identified in reducing liver transplants or SAEs. Long-term administration may be associated with a lower risk of cirrhosis complications and need for paracentesis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Leache L, Gutiérrez-Valencia M, Saiz LC, et al. Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis. Aliment Pharmacol Ther. 2022. PMID: 36524316. doi:10.1111/apt.17344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。